Diabetes Therapy最新文献

{"title":"Time Trends of Body Mass Index and its Impact on Glycemic Control Among Finnish Patients with Type 2 Diabetes.","authors":"Zhiting Wang, Piia Lavikainen, Katja Wikström, Tiina Laatikainen","doi":"10.1007/s13300-025-01763-2","DOIUrl":"https://doi.org/10.1007/s13300-025-01763-2","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity prevalence has increased in Finland and is prevalent in patients with type 2 diabetes (T2D). Also, hyperglycemia in patients with T2D is partially attributed to obesity. We aimed to examine the time trends of body mass index (BMI) and glycated hemoglobin (HbA1c) control across different BMI categories among Finnish patients with T2D.</p><p><strong>Methods: </strong>Regional data on the electronic health records (EHRs) covering all public healthcare services in North Karelia, Finland, were used to conduct this retrospective study. Annual patients with T2D from 2012 to 2022 were identified from the EHRs. In each study year, patients with ≥ 1 measurement of BMI and HbA1c were included. Linear and logistic regression analyses estimated with generalized estimating equations were performed to evaluate the time trends.</p><p><strong>Results: </strong>The annual number of patients for analyses ranged from 5149 to 10,216 during 2012-2022. The unadjusted mean BMI declined slightly over time but increased after age adjustment (all p < 0.05). In the age-stratified analysis adjusted for sex and diabetes duration, mean BMI increased over time in patients aged 45-64 years (all p < 0.05). Furthermore, the increasing time trend in age-adjusted BMI among the study patients persisted after adjusting for sex, diabetes duration, and antidiabetic medication use (p < 0.05). Overall, patients in the higher BMI categories had higher HbA1c levels and were less likely to achieve the HbA1c target from 2012 to 2022. When examining time trends of HbA1c control, HbA1c control improved over time in patients with the highest level of BMI, coinciding with a greater increase in new antidiabetic medication use compared with the lowest BMI group (p < 0.05 for calendar year × obesity class III interaction).</p><p><strong>Conclusion: </strong>Our findings suggest that weight management requires increased attention among Finnish patients with T2D and is especially important for better glycemic control.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Predictive Value of Insulin Resistance Surrogates for Diabetic Kidney Disease in Type 2 Diabetes Mellitus.","authors":"Qiuying Sun, Meiru Zhao, Xiaonan Wang, Jiangteng Wang, Yaxi Yang, Lin Liu, Di Zhu, Xu Li, Qingbo Guan, Xu Zhang","doi":"10.1007/s13300-025-01765-0","DOIUrl":"https://doi.org/10.1007/s13300-025-01765-0","url":null,"abstract":"<p><strong>Introduction: </strong>Insulin resistance (IR) is a major feature of type 2 diabetes mellitus (T2DM) and plays a crucial role in the accelerated progression of diabetic kidney disease (DKD). It has been found that surrogates of IR are of high value in assessing IR status. This study aims to evaluate the associations between surrogates of IR and DKD in T2DM.</p><p><strong>Methods: </strong>A total of 1026 patients with T2DM from January 2021 to February 2022 were selected in our final analysis. Logistic regression analysis and the receiver operating characteristic (ROC) curve analysis were performed to assess the correlation between IR surrogates and DKD.</p><p><strong>Results: </strong>The levels of triglyceride glucose-waist circumference (TyG-WC), triglyceride glucose-waist to height ratio (TyG-WHtR), visceral adiposity index (VAI), and lipid accumulation product (LAP) were significantly higher in the microalbuminuria group and macroalbuminuria group compared with the normoalbuminuria group (P < 0.05). The results of multivariate logistic regression analysis showed that the highest quartile of triglyceride/high-density lipoprotein cholesterol ratio (TG/HDL-C), triglyceride glucose (TyG) index, TyG-WHtR, TyG-WC, LAP, and VAI were significantly correlated with DKD (all P < 0.05). The ROC curves and results showed that TyG area under the curve (AUC) > VAI AUC > TG/HDL-C AUC > TyG-WHtR AUC > LAP AUC > 0.7 > TyG-WC AUC > metabolic index of insulin resistance (METS-IR) AUC > 0.6 > triglyceride glucose-body mass index (TyG-BMI) AUC > 0.5.</p><p><strong>Conclusions: </strong>The predictive value of IR surrogates for DKD in T2DM varies. TG/HDL-C, TyG, TyG-WHtR, LAP, and VAI can effectively predict DKD and are expected to be simple and economic biological indicators of DKD risk.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies.","authors":"Salvatore Corrao, Fabio Falcone, Luigi Mirarchi, Simona Amodeo, Luigi Calvo","doi":"10.1007/s13300-025-01761-4","DOIUrl":"https://doi.org/10.1007/s13300-025-01761-4","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a global health priority, with an estimated 629 million people projected to be affected by the year 2045. T2DM significantly increases the risk of atherosclerotic cardiovascular disease and other complications. Hyperglycaemia imprints early molecular and cellular changes, often termed \"metabolic memory\", predisposing individuals to long-term microvascular and macrovascular complications, even after glycaemic normalisation. T2DM remission is increasingly recognised as an achievable target, offering substantial benefits such as reduced morbidity, improved quality of life, and preservation of beta-cell function. Among therapeutic options, metabolic surgery (MS) demonstrates the most significant impact, particularly for long-term outcomes. MS induces profound hormonal changes, including increased glucagon-like peptide 1 (GLP-1) levels and improved bile acid metabolism, alongside reductions in ectopic fat in the liver and pancreas, which improve insulin sensitivity and secretion. However, intensive lifestyle and pharmacological interventions, such as GLP-1 receptor agonists and glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 dual agonists like tirzepatide, also show promise, particularly when implemented early in the disease course. Predictors of sustained remission include younger age, shorter diabetes duration, lower baseline HbA1c, absence of insulin use, fewer medications and greater total weight loss percentage. Emerging tools such as the DiaRem score, machine learning models, and biomarkers like FGF-21 enhance patient stratification and predict remission likelihood. This narrative review explores the mechanisms and therapeutic options for T2DM remission, evaluates their impact on long-term outcomes and highlights the importance of early, multidisciplinary, and personalised interventions to optimize remission and improve metabolic health.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Baseline Diabetes Therapy-Related Quality of Life (DTR-QOL) and Subsequent Risk of All-Cause Mortality: A Prospective Cohort Study (Diabetes Distress and Care Registry at Tenri [DDCRT 26]).","authors":"Yuichi Nishioka, Yasuaki Hayashino, Kentaro Kurosawa, Kiyoko Takano, Satoshi Matsunaga, Shintaro Okamura, Satoru Tsujii, Hitoshi Ishii","doi":"10.1007/s13300-025-01755-2","DOIUrl":"https://doi.org/10.1007/s13300-025-01755-2","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to examine a cohort of people with diabetes to prospectively determine the association between diabetes therapy-related quality of life (DTR-QOL) and the subsequent risk of all-cause mortality.</p><p><strong>Methods: </strong>Longitudinal data of 3795 individuals with diabetes were obtained from a single-center diabetes registry from 2011. To assess the association between DTR-QOL at baseline and the subsequent risk of all-cause mortality, a Cox proportional hazards model was used with adjustment for baseline potential confounders (age, sex, duration of diabetes, body mass index [BMI], glycated hemoglobin [HbA1c] level, urinary albumin/creatinine ratio, history of diabetic retinopathy, symptomatic diabetic neuropathy, medical history, type of diabetes, and diabetes prescriptions).</p><p><strong>Results: </strong>We observed 425 deaths during a median follow-up of 8.7 years. The median (interquartile range) age and HbA1c level were 66 (60-74) years and 6.9% (6.7-8.1%), respectively. The DTR-QOL was significantly associated with younger age, female sex, higher BMI, higher HbA1c level, higher proportion of symptomatic diabetic neuropathy, higher proportion of diabetic retinopathy, and higher proportion of insulin use. In total, 425 deaths occurred during the study period. Compared with the third tertile group of DTR-QOL scores, the hazard ratios (HRs) were consistently 1.38 times higher in the first tertile group. Lower scores on \"burden on social activities and daily activities\" domain were associated with a higher HR, while lower scores on the other domains (\"anxiety and dissatisfaction with therapy,\" \"hypoglycemia,\" and \"satisfaction with therapy\") were not.</p><p><strong>Conclusion: </strong>A lower QOL related to diabetes therapy in people with diabetes was found to be associated with an increased risk of future mortality. Graphical Abstract available for this article.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous Glucose Monitoring Among People with and without Diabetes Mellitus and Sleep Apnoea.","authors":"Evanthia Gouveri, Fotios Drakopanagiotakis, Theodoros Panou, Dimitrios Papazoglou, Paschalis Steiropoulos, Nikolaos Papanas","doi":"10.1007/s13300-025-01756-1","DOIUrl":"https://doi.org/10.1007/s13300-025-01756-1","url":null,"abstract":"<p><p>The association of sleep apnoea with insulin resistance and type 2 diabetes mellitus (T2DM) is well studied. However, little is known on the impact of sleep apnoea on glycaemic variability (GV). Continuous glucose monitoring (CGM) systems shed light on GV not only during sleep but throughout the day among people with or without diabetes mellitus (DM) and obstructive sleep apnoea syndrome (OSAS). In this narrative review, we aimed to summarise the evidence on the role of CGM in assessing GV among individuals with sleep apnoea. Articles related to CGM use among individuals with OSAS were included. Emerging data suggests a significant impact of OSAS on glucose metabolism during sleep and wakefulness. Of note, OSAS affects GV irrespective of glycaemic status. Moreover, the severity of OSAS has been associated with increased GV. As GV triggers oxidative stress, it contributes to adverse outcomes in people with diabetes and/or OSAS. Interestingly, a beneficial effect of continuous positive airway pressure (CPAP) treatment on blood glucose and on GV in individuals with both T2DM and OSAS has emerged, but evidence is conflicting. Additionally, among pregnant women with gestational diabetes and sleep-disordered breathing, CGM could detect nocturnal hyperglycaemic episodes, improving glycaemic control and perinatal outcomes. Future studies are needed to investigate the exact impact of OSAS treatment on GV.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Association Between Type 2 Diabetes Mellitus and Heart Failure: A Retrospective Study from a Tertiary Care Diabetes Centre in India.","authors":"Rajendra Pradeepa, Thyparambil Aravindakshan PramodKumar, Ranjit Mohan Anjana, Saravanan Jebarani, Abdul Subhan Naziyagulnaaz, Sadasivam Ganesan, Natarajan Premananth, Abraham Oomman, Soumitra Kumar, Pathiyil Balagopalan Jayagopal, Gurpreet Singh Wander, Ajit Mullasari, Jagat Narula, Sanjay Jain, Onkar C Swami, Viswanathan Mohan","doi":"10.1007/s13300-025-01758-z","DOIUrl":"https://doi.org/10.1007/s13300-025-01758-z","url":null,"abstract":"","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.","authors":"J Bradley Layton, Ryan Ziemiecki, Catherine B Johannes, Manel Pladevall-Vila, Anam M Khan, Natalie Ebert, Csaba P Kovesdy, Christian Fynbo Christiansen, Aníbal García-Sempere, Hiroshi Kanegae, Craig I Coleman, Michael Walsh, Ina Trolle Andersen, Clara Rodríguez-Bernal, Celia Robles Cabaniñas, Reimar W Thomsen, Alfredo E Farjat, Alain Gay, Patrick Gee, Isabel Hurtado, Naoki Kashihara, Philip Vestergaard Munch, Fangfang Liu, Suguru Okami, Satoshi Yamashita, Yuichiro Yano, David Vizcaya, Nikolaus G Oberprieler","doi":"10.1007/s13300-025-01750-7","DOIUrl":"https://doi.org/10.1007/s13300-025-01750-7","url":null,"abstract":"<p><strong>Introduction: </strong>People with chronic kidney disease (CKD) and type 2 diabetes (T2D) have an increased risk of kidney failure and cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have shown cardiorenal protective effects. The objective of this multinational, multidatabase study was to describe the incidence of kidney and cardiovascular outcomes in separate, non-mutually exclusive cohorts of patients with CKD and T2D who initiated either an SGLT2i or a GLP-1 RA.</p><p><strong>Methods: </strong>Data describing adults (≥ 18 years) with T2D and CKD who were new users of either SGLT2i or GLP-1 RA from 2012 to 2019 were assessed from population-based Danish National Health Registers (DNHR) and Valencia Health System Integrated Database (VID), hospital-based Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex), and US Optum^® de-identified Electronic Health Record dataset (Optum^® EHR). Crude incidence rates (IRs) and 95% confidence intervals (CIs) for primary outcomes (kidney failure, acute coronary syndrome, stroke, new-onset congestive heart failure, new-onset atrial fibrillation) and cumulative incidence by follow-up time for primary and secondary outcomes (laboratory measurements of kidney function) were estimated.</p><p><strong>Results: </strong>SGLT2i cohorts comprised 12,501 patients in DNHR, 22,404 in VID, 811 in J-CKD-DB-Ex, and 54,308 in Optum^® EHR. GLP-1 RA cohorts comprised 10,696 in DNHR, 8317 in VID, 219 in J-CKD-DB-Ex, and 78,934 in Optum^® EHR. Baseline clinical profile differences were observed for GLP-1 RA and SGLT2i new users, and crude IRs of kidney and heart failure tended to be higher in the GLP-1 RA cohorts than in the SGLT2i cohorts across data sources.</p><p><strong>Conclusion: </strong>Understanding the incidence of kidney failure and cardiovascular outcomes in people receiving antidiabetic medications with cardiorenal protective effects is important for future studies aiming to compare the incidence of kidney and cardiovascular outcomes related to new and existing CKD treatments.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec.","authors":"Athena Philis-Tsimikas, Julie Krogsdahl Bache, Ariel Fu, Monika Kellerer, Karen Salvesen-Sykes, Stephen C Bain","doi":"10.1007/s13300-025-01745-4","DOIUrl":"https://doi.org/10.1007/s13300-025-01745-4","url":null,"abstract":"<p><strong>Introduction: </strong>The ONWARDS programme assessed the efficacy and safety of once-weekly insulin icodec (icodec) versus once-daily basal insulin comparators in type 2 diabetes (T2D) or type 1 diabetes (T1D). This post hoc exploratory analysis of ONWARDS 1-6 assessed the impact of icodec during and around hospitalisation.</p><p><strong>Methods: </strong>ONWARDS 1-6 were randomised, two-arm, phase 3a trials (ClinicalTrials.gov: NCT04460885; NCT04770532; NCT04795531; NCT04880850; NCT04760626; NCT04848480). Adults with T2D (ONWARDS 1-5; n = 3765) and T1D (ONWARDS 6; n = 582) received icodec or once-daily comparators (insulin degludec, insulin glargine U100, insulin glargine U300). Hospitalised cases were analysed for: hospitalisation duration, icodec dose, self-measured blood glucose, glycated haemoglobin (HbA_1c) levels, and clinically significant and severe hypoglycaemia before, during, and after hospitalisation.</p><p><strong>Results: </strong>Across trials, a similar number of participants receiving icodec (n = 152/2172) and once-daily comparators (n = 156/2175) were hospitalised. Median duration of hospital stay was similar between treatment groups (icodec, 5.0 days; once-daily comparators, 6.0 days); icodec dose remained fairly stable around hospitalisation. Most hospitalised participants completed the trial without permanently discontinuing treatment (icodec, 84.9%; once-daily comparators, 90.4%). Mean HbA_1c levels remained relatively stable over assessed time points for both treatment groups. Six participants receiving icodec (one with T2D; five with T1D) and three receiving once-daily comparators (one with T2D; two with T1D) reported clinically significant or severe hypoglycaemia during hospitalisation.</p><p><strong>Conclusions: </strong>Similar numbers of hospitalisations were reported in both treatment arms. Icodec treatment was continued during hospitalisation in most participants and did not appear to have an impact on glycaemic management or hypoglycaemia. This analysis suggests that once-weekly icodec could be managed in a similar way to once-daily basal insulin analogues during hospitalisation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifiers, NCT04460885 (ONWARDS 1), NCT04770532 (ONWARDS 2), NCT04795531 (ONWARDS 3), NCT04880850 (ONWARDS 4), NCT04760626 (ONWARDS 5), NCT04848480 (ONWARDS 6).</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Potential of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Peripheral Neuropathy.","authors":"Theodoros Panou, Evanthia Gouveri, Djordje S Popovic, Dimitrios Papazoglou, Nikolaos Papanas","doi":"10.1007/s13300-025-01712-z","DOIUrl":"10.1007/s13300-025-01712-z","url":null,"abstract":"<p><p>Diabetic peripheral neuropathy (DPN) is one of the commonest complications of diabetes mellitus (DM). Current therapeutic approaches largely focus on pain management. However, less evidence is available on the clinical potential of two widely prescribed drug categories in DM management: dipeptidyl peptidase 4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs). In this review, we discuss evidence from both experimental and clinical studies on the potential utility of these drugs in the management of DPN. Immunohistochemical data indicate that agents in both categories promote neurite outgrowth, ion conduction, neuronal survival and Schwann cell function. Furthermore, intra-epidermal nerve fibre density has been reported to increase with DPP-4is or GLP-1RAs treatment. Moreover, electrophysiological studies have indicated a diverse, but mostly beneficial, effect on motor or sensory nerve conduction velocity. Clinical tests, such as the muscular grip or paw jumping control resembling neuropathic symptoms, have also confirmed the advantageous effect of DPP-4is and GLP-1RAs. Finally, limited but promising clinical data have shown improved somatosensory-evoked potentials and vibration perception threshold, as well as restored excitability and nerve size parameters. Nevertheless, further clinical studies are required to elucidate the exact role of DPP-4is and GLP-1RAs in DPN.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1077-1105"},"PeriodicalIF":3.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Serum SERPINE2 Levels are Linked to Impaired Renal Function in Patients with Type 2 Diabetes Mellitus.","authors":"Shudan Cao, Qing Tan, Lijuan Yang","doi":"10.1007/s13300-025-01742-7","DOIUrl":"10.1007/s13300-025-01742-7","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic nephropathy (DN) is the primary complication associated with diabetes mellitus and is increasingly acknowledged as the leading cause of end-stage renal disease worldwide, placing a significant economic burden on society. This study determined how blood serpin peptidase inhibitor clade E member 2 (SERPINE2) levels affect DN in individuals with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>We recruited 292 individuals diagnosed with T2DM and 120 healthy controls for this study. We employed comprehensive and systematic data collection methodologies to gather relevant biomarkers and information on biochemical parameters. We measured serum levels of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), transforming growth factor-β1 (TGFβ1), connective tissue growth factor (CTGF), and SERPINE2 by the enzyme-linked immunosorbent assay in control subjects and patients with T2DM. We calculated generalized odds ratios (OR) to estimate the risk of developing DN.</p><p><strong>Results: </strong>Patients with diabetes had significantly higher levels of SERPINE2 (285.64 ± 56.58 pg/mL) than healthy controls (184.84 ± 23.54 pg/mL). Additionally, the multivariate logistic regression analysis indicated that patients with diabetes with DN possessed higher levels of serum SERPINE2 (OR 1.033, 95% confidence interval [CI] 1.013-1.053; P = 0.001), along with an increased body mass index (BMI), duration of diabetes, serum creatinine (Scr), NGAL, KIM-1, TGFβ1, and CTGF. Receiver operating characteristic (ROC) curve analysis indicated that patients with T2DM and serum SERPINE2 levels exceeding 278.94 pg/mL had a significantly higher risk of developing DN.</p><p><strong>Conclusion: </strong>The results showed that patients with diabetes with DN have higher levels of serum SERPINE2. A more extensive population-based prospective study is needed to validate our findings.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1313-1326"},"PeriodicalIF":3.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}